<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35532872</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-6903</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>Neurochemical research</Title>
          <ISOAbbreviation>Neurochem Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The Anti-Parkinson Potential of Gingko biloba-Supplement Mitigates Cortico-Cerebellar Degeneration and Neuropathobiological Alterations via Inflammatory and Apoptotic Mediators in Mice.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11064-022-03600-5</ELocationID>
        <Abstract>
          <AbstractText>Activation of nuclear factor erythroid 2 related factor 2 (Nrf2) associated with the suppression of various oxido-inflammatory pathways and the controller of several gene expressions involving "antioxidant response elements" (AREs) in their promoters to mediate and restores homeostatic functions is now considered as one of the main switch regulating the immune response, and it is also now involved in inflammatory cascade in PD. Whether therapeutic approach using Ginkgo biloba would have significant protective effects against cortico-cerebellar dopaminergic degeneration in rotenone-induced mice remains unknown. In this present study, we studied the therapeutic effects of Ginkgo biloba-supplement (Gb-S) administration in cortico-cerebellar dopaminergic degeneration. The results revealed that treatment with Gb-S suppresses cognitive decline and neuromuscular incompetence in the mice, abated tyrosine hydroxylase depletion and synucleinopathy development in the cortico-cerebellar neurons of the mice before and after rotenone induction. However, our data further shows increase Nrf2 immunoexpression with decrease oxido-nitrergic and neuroinflammatory release, increase cholinergic enzyme activity and downregulated executioner caspase-3 that may mediate cortico-cerebellar apoptosis. Also, the loss of cortico-cerebellar neurons was attenuated, marked by increase in dendritic spine length and width with numerous viable neurons. Overall findings suggest that Gb-S could be a potential pharmacotherapeutic candidate providing a strong protection for cortico-cerebellar neurocellular substances and against Parkinsonism-like non-motor and motor symptoms.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Adebayo</LastName>
            <ForeName>Olusegun G</ForeName>
            <Initials>OG</Initials>
            <Identifier Source="ORCID">0000-0001-6654-2564</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Basic Medical Sciences, Department of Physiology, Neurophysiology Unit, PAMO University of Medical Sciences, Port-Harcourt, River State, Nigeria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aduema</LastName>
            <ForeName>Wadioni</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Basic Medical Sciences, Department of Physiology, Bayelsa Medical University, Yenagoa, Bayelsa State, Nigeria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Emmanuel</LastName>
            <ForeName>Modo U</ForeName>
            <Initials>MU</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Basic Medical Sciences, Department of Biochemistry, PAMO University of Medical Sciences, Port-Harcourt, River State, Nigeria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ben-Azu</LastName>
            <ForeName>Benneth</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0003-3569-3575</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Basic Medical Sciences, Department of Pharmacology and Therapeutics, College of Health Sciences, Delta State University, Abraka, Delta State, Nigeria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Orji</LastName>
            <ForeName>Blessing O</ForeName>
            <Initials>BO</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Life Sciences, Department of Biochemistry &amp; Molecular Biology, Federal University Dutsin-Ma, Dutsin-Ma, Katsina State, Nigeria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akpakpan</LastName>
            <ForeName>Ekam</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Basic Medical Sciences, Department of Pharmacology and Therapeutics, College of Health Sciences, Delta State University, Abraka, Delta State, Nigeria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adebayo</LastName>
            <ForeName>Oluwakemi Rachael</ForeName>
            <Initials>OR</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Public Health, Department of Human Nutrition and Dietetics, University of Ibadan, Ibadan, Oyo State, Nigeria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Onuoha</LastName>
            <ForeName>Ogechukwu G</ForeName>
            <Initials>OG</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Basic Medical Sciences, Department of Physiology, Neurophysiology Unit, PAMO University of Medical Sciences, Port-Harcourt, River State, Nigeria.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ajayi</LastName>
            <ForeName>Abayomi M</ForeName>
            <Initials>AM</Initials>
            <Identifier Source="ORCID">0000-0001-6586-0421</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Basic Medical Sciences, Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Oyo State, Nigeria. yomexj@yahoo.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Neurochem Res</MedlineTA>
        <NlmUniqueID>7613461</NlmUniqueID>
        <ISSNLinking>0364-3190</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antioxidant</Keyword>
        <Keyword MajorTopicYN="N">Cortico-cerebellum</Keyword>
        <Keyword MajorTopicYN="N">Ginkgo biloba</Keyword>
        <Keyword MajorTopicYN="N">Neuroinflammation</Keyword>
        <Keyword MajorTopicYN="N">Nrf2</Keyword>
        <Keyword MajorTopicYN="N">Parkinson’s disease</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>9</Day>
          <Hour>11</Hour>
          <Minute>18</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35532872</ArticleId>
        <ArticleId IdType="doi">10.1007/s11064-022-03600-5</ArticleId>
        <ArticleId IdType="pii">10.1007/s11064-022-03600-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Liu J, Liu W, Lu Y et al (2018) Piperlongumine restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models. Autophagy 14:845–861</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29433359</ArticleId>
            <ArticleId IdType="pmc">6070010</ArticleId>
            <ArticleId IdType="doi">10.1080/15548627.2017.1390636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin MS, Kim TW, Lee JM et al (2017) Treadmill exercise alleviates nigrostriatal dopaminergic loss of neurons and fibers in rotenone-induced Parkinson rats. J Exerc Rehabilitat 13:30</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.12965/jer.1734906.453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fonseca-Fonseca LA, da Silva VD, Wong-Guerra M et al (2021) JM-20 protects against 6-hydroxydopamine-induced neurotoxicity in models of Parkinson’s disease: mitochondrial protection and antioxidant properties. Neurotoxicology 82:89–98</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33232743</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neuro.2020.11.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schapira AH (2009) Etiology and pathogenesis of Parkinson disease. Neurol Clin 27:583–603</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19555823</ArticleId>
            <ArticleId IdType="doi">10.1016/j.ncl.2009.04.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antony PM, Diederich NJ, Kruger R et al (2013) The hallmarks of Parkinson’s disease. FEBS J 280:5981–5993. https://doi.org/10.1111/febs.12335</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/febs.12335</ArticleId>
            <ArticleId IdType="pubmed">23663200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verstraeten A, Theuns J, Van Broeckhoven C (2015) Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet 31:140–149</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25703649</ArticleId>
            <ArticleId IdType="doi">10.1016/j.tig.2015.01.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorsey ER, Constantinescu R, Thompson JP et al (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384–386</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17082464</ArticleId>
            <ArticleId IdType="doi">10.1212/01.wnl.0000247740.47667.03</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Savica R, Grossardt BR, Rocca WA et al (2018) Parkinson disease with and without Dementia: a prevalence study and future projections. Mov Disord 33:537–543</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29356127</ArticleId>
            <ArticleId IdType="pmc">5892791</ArticleId>
            <ArticleId IdType="doi">10.1002/mds.27277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gill EL, Raman S, Yost RA et al (2018) L-Carnitine inhibits lipopolysaccharide-induced nitric oxide production of SIM-A9 microglia cells. ACS Chem Neurosci 9:901–905</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29370524</ArticleId>
            <ArticleId IdType="doi">10.1021/acschemneuro.7b00468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bento-Pereira C, Dinkova-Kostova AT (2021) Activation of transcription factor Nrf2 to counteract mitochondrial dysfunction in Parkinson’s disease. Med Res Rev 41:785–802</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32681666</ArticleId>
            <ArticleId IdType="doi">10.1002/med.21714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lohani S, Martig AK, Deisseroth K et al (2019) Dopamine modulation of prefrontal cortex activity is manifold and operates at multiple temporal and spatial scales. Cell Rep 27:99–114</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30943418</ArticleId>
            <ArticleId IdType="doi">10.1016/j.celrep.2019.03.012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawabata K, Watanabe H, Bagarinao E et al (2020) Cerebello-basal ganglia connectivity fingerprints related to motor/cognitive performance in Parkinson’s disease. Parkinsonism Relat Disord 80:21–27</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32932024</ArticleId>
            <ArticleId IdType="doi">10.1016/j.parkreldis.2020.09.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stuart S, Morris R, Giritharan A et al (2019) Prefrontal cortex activity and gait in Parkinson’s disease with cholinergic and dopaminergic therapy. Mov Disord 35:2019–2027</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.28214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tucker HR, Mahoney E, Akhtar K et al (2021) Motor thalamic deep brain stimulation alters cortical activity and shows therapeutic utility for treatment of Parkinson’s disease symptoms in a rat model. Neuroscience 460:88–106</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33631218</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2021.02.019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ott T, Nieder A (2019) Dopamine and cognitive control in prefrontal cortex. Trends Cogn Sci 23:213–234</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30711326</ArticleId>
            <ArticleId IdType="doi">10.1016/j.tics.2018.12.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Orcioli-Silva D, Vitório R, Nóbrega-Sousa P et al (2020) Levodopa facilitates prefrontal cortex activation during dual task walking in Parkinson disease. Neurorehabil Neural Repair 34:589–599</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32449460</ArticleId>
            <ArticleId IdType="doi">10.1177/1545968320924430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Festini SB, Bernard JA, Kwak Y et al (2015) Altered cerebellar connectivity in Parkinson’s patients ON and OFF L-DOPA medication. Front Hum Neurosci 9:1–13</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnhum.2015.00214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maiti B, Koller JM, Snyder AZ (2020) Cognitive correlates of cerebellar Resting-state functional connectivity in Parkinson disease. Neurology. https://doi.org/10.1212/WNL.0000000000008754</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000008754</ArticleId>
            <ArticleId IdType="pubmed">31848257</ArticleId>
            <ArticleId IdType="pmc">7079688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hogan MJ (2004) The cerebellum in thought and action: a fronto-cerebellar aging hypothesis. New Ideas Psychol 22:97–125</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.newideapsych.2004.09.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Hoorn A, Renken RJ, Leenders KL et al (2014) Parkinson-related changes of activation in visuomotor brain regions during perceived forward self-motion. PLoS One 9:e95861</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24755754</ArticleId>
            <ArticleId IdType="pmc">3995937</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0095861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bosch TJ, Groth C, Eldridge TA et al (2021) Altered cerebellar oscillations in Parkinson’s disease patients during cognitive and motor tasks. Neuroscience 475:185–196</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34455014</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neuroscience.2021.08.021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaudhuri KR, Healy DG, Schapira AH (2006) National Institute for Clinical E. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5:235–245</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16488379</ArticleId>
            <ArticleId IdType="doi">10.1016/S1474-4422(06)70373-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramsay RR, Popovic-Nikolic MR, Nikolic K et al (2018) A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med 7:3. https://doi.org/10.1186/s40169-017-0181-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40169-017-0181-2</ArticleId>
            <ArticleId IdType="pubmed">29340951</ArticleId>
            <ArticleId IdType="pmc">5770353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas P, Serrano-Garcia N, Mares-Samano JJ et al (2008) EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress. Eur J Neurosci 28:141–150</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1460-9568.2008.06314.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohammed NA, Abdou HM, Tass MA et al (2020) Oral supplements of Ginkgo biloba extract alleviate neuroinflammation, oxidative impairments and neurotoxicity in rotenone-induced Parkinsonian rats. Curr Pharm Biotechnol 21:1259–1268</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32196446</ArticleId>
            <ArticleId IdType="doi">10.2174/1389201021666200320135849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma N, Jamwal S, Kumar P (2016) Beneficial effect of antidepressants against rotenone induced Parkinsonism like symptoms in rats. Pathophysiology 23:123–134</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26996500</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pathophys.2016.03.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adebayo OG, Ben-Azu B, Ajayi AM et al (2021) Gingko biloba abrogate lead-induced neurodegeneration in mice hippocampus: involvement of NF-κB expression, myeloperoxidase activity and pro-inflammatory mediators. Biol Trace Elem Res 9:1–4</Citation>
        </Reference>
        <Reference>
          <Citation>Eduviere AT, Umukoro S, Aderibigbe AO et al (2015) Methyljasmonate enhances memory performance through inhibition of oxidative stress and acetylcholinesterase activity in mice. Life Sci 132:20–26</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25921767</ArticleId>
            <ArticleId IdType="doi">10.1016/j.lfs.2015.04.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Montoya CP, Campbell-Hope LJ, Pemberton KD et al (1991) The “staircase test”: a measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods 36:219–228. https://doi.org/10.1016/0165-0270(91)90048-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0165-0270(91)90048-5</ArticleId>
            <ArticleId IdType="pubmed">2062117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dereli FTG, Ilhan M, Akkol EK (2018) Discovery of new antidepressant agents: In vivo study on Anthemis wiedemanniana Fisch. &amp; Mey. J Ethnopharmacol 226:11–16</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jep.2018.07.019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruhela RK, Soni S, Sarma P et al (2019) Negative geotaxis: an early age behavioral hallmark to VPA rat model of autism. Ann Neurosci 26:25–31. https://doi.org/10.5214/ans.0972.7531.260106</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5214/ans.0972.7531.260106</ArticleId>
            <ArticleId IdType="pubmed">31975769</ArticleId>
            <ArticleId IdType="pmc">6894633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradford M (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–252</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">942051</ArticleId>
            <ArticleId IdType="doi">10.1016/0003-2697(76)90527-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varshney R, Kale R (1990) Effect of calmodulin antagonists on radiation induced lipid peroxidation in microsomes. Int J Radiat Biol 58:733–743</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1977818</ArticleId>
            <ArticleId IdType="doi">10.1080/09553009014552121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onasanwo SA, Adamaigbo VO, Adebayo OG et al (2021) Moringa oleifera-supplemented diet protect against cortico-hippocampal neuronal degeneration in scopolamine-induced spatial memory deficit in mice: role of oxido-inflammatory and cholinergic neurotransmission pathway. Metab Brain Dis 36:2445–2460</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34669098</ArticleId>
            <ArticleId IdType="doi">10.1007/s11011-021-00855-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green LC, Wagner DA, Glogowski J et al (1982) Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 126:131–138</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7181105</ArticleId>
            <ArticleId IdType="doi">10.1016/0003-2697(82)90118-X</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clairborne A (1995) Catalase activity. CRC Press, Florida, Handbook of Methods for Oxygen Radical Research</Citation>
        </Reference>
        <Reference>
          <Citation>Habig WH, Pabst MJ, Jakoby WB (1974) Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130–7139</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4436300</ArticleId>
            <ArticleId IdType="doi">10.1016/S0021-9258(19)42083-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jollow D, Mitchell J, Zampaglione N et al (1974) Bromobenzene induced liver necrosis: protective role of glutathione and evidence for 3, 4 bromobenzene oxide as the hepatotoxic metabolite. Pharmacology 11:151–169</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4831804</ArticleId>
            <ArticleId IdType="doi">10.1159/000136485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellman GL, Courtney KD, Andres V Jr et al (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1:88–95</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-2952(61)90145-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wopara I, Modo EU, Adebayo OG et al (2021) Anxiogenic and memory impairment effect of food color exposure: upregulation of oxido-neuroinflammatory markers and acetyl-cholinestrase activity in the prefrontal cortex and hippocampus. Heliyon 1(7):e06378</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.heliyon.2021.e06378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradley PP, Priebat DA, Christensen RD et al (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78:206–209</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6276474</ArticleId>
            <ArticleId IdType="doi">10.1111/1523-1747.ep12506462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edelstein AD, Tsuchida MA, Amodaj N et al (2014) Advanced methods of microscope control using μManager software. J Biol Methods 7:1</Citation>
        </Reference>
        <Reference>
          <Citation>Wu A, Liu Y (2000) Apoptotic cell death in rat brain following deltamethrin treatment. Neurosci Lett 279:85–88</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10674627</ArticleId>
            <ArticleId IdType="doi">10.1016/S0304-3940(99)00973-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angulo E, Fernandez JA, Merchan M et al (1996) A reliable method for Golgi staining of retina and brain slices. J Neurosci Methods 66:55–59</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8794940</ArticleId>
            <ArticleId IdType="doi">10.1016/0165-0270(95)00160-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deleu D, Northway MG, Hanssens Y (2002) Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 41:261–309</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11978145</ArticleId>
            <ArticleId IdType="doi">10.2165/00003088-200241040-00003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farombi EO, Awogbindin IO, Olorunkalu PD et al (2020) Kolaviron protects against nigrostriatal degeneration and gut oxidative damage in a stereotaxic rotenone model of Parkinson’s disease. Psychopharmacology 237:3225–3236</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32651640</ArticleId>
            <ArticleId IdType="doi">10.1007/s00213-020-05605-w</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang XL, Huang WM, Tang PC et al (2021) Anti-inflammatory and neuroprotective effects of natural cordycepin in rotenone-induced PD models through inhibiting Drp1-mediated mitochondrial fission. Neurotoxicology 84:1–3</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33549657</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neuro.2021.02.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassan IM, Abdullahi AM (2021) Recent studies on the therapeutic and prophylactic effect of some agents on experimental induced Parkinson disease models review. Asian J Res Biochem 23:1–8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.9734/ajrb/2021/v8i230175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuang S, Yang L, Rao Z et al (2018) Effects of Ginkgo biloba extract on A53T α-synuclein transgenic mouse models of Parkinson’s disease. Can J Neurol Sci 45:182–187</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29506601</ArticleId>
            <ArticleId IdType="doi">10.1017/cjn.2017.268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu D, Zhang P, Li J et al (2021) Neuroprotective effects of Ginkgo biloba dropping pills in Parkinson’s disease. J Pharm Anal 1:220–231</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpha.2020.06.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez-Baltazar D, Mendoza-Garrido ME, Martinez-Fong D (2013) Activation of GSK-3β and caspase-3 occurs in nigral dopamine neurons during the development of apoptosis activated by a striatal injection of 6-hydroxydopamine. PloS one 8:e70951</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23940672</ArticleId>
            <ArticleId IdType="pmc">3733721</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0070951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui Q, Li X, Zhu H (2016) Curcumin ameliorates dopaminergic neuronal oxidative damage via activation of the Akt/Nrf2 pathway. Mol Med Rep 13:1381–1388</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26648392</ArticleId>
            <ArticleId IdType="doi">10.3892/mmr.2015.4657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee JA, Son HJ, Choi JW et al (2018) Activation of the Nrf2 signaling pathway and neuroprotection of nigral dopaminergic neurons by a novel synthetic compound KMS99220. Neurochem Int 112:96–107</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29158022</ArticleId>
            <ArticleId IdType="doi">10.1016/j.neuint.2017.11.006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou XD, Wang JL, Guo DD et al (2021) Neuroprotective effect of targeted regulatory Nrf2 gene on rats with acute brain injury induced by carbon monoxide poisoning. Environ Toxicol 36:1742–1757</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34032369</ArticleId>
            <ArticleId IdType="doi">10.1002/tox.23295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco-Iborra S, Vila M, Perier C (2018) Mitochondrial quality control in neurodegenerative diseases: focus on Parkinson’s disease and Huntington’s disease. Front Neurosci 23(12):342</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2018.00342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khatri DK, Juvekar AR (2016) Neuroprotective effect of curcumin as evinced by abrogation of rotenone-induced motor deficits, oxidative and mitochondrial dysfunctions in mouse model of Parkinson’s disease. Pharmacol Biochem Behav 150:39–47</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27619637</ArticleId>
            <ArticleId IdType="doi">10.1016/j.pbb.2016.09.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur K, Gill JS, Bansal PK et al (2017) Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson’s Disease. J Neurol Sci 381:308–314. https://doi.org/10.1016/j.jns.2017.08.3251</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2017.08.3251</ArticleId>
            <ArticleId IdType="pubmed">28991704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ojha S, Javed H, Azimullah S et al (2015) Neuroprotective potential of ferulic acid in the rotenone model of Parkinson’s disease. Drug Des Dev Ther 9:5499–5510. https://doi.org/10.2147/DDDT.S90616</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/DDDT.S90616</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
